Creating new drugs to reduce inflammation in Alzheimer's disease
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease
This study is working on new treatments that could help slow down Alzheimer's disease by reducing inflammation in the brain, using special compounds that have shown promise in early tests with animals.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11094851 on NIH RePORTER |
What this research studies
This research focuses on developing new inhibitors that target the NLRP3 inflammasome, a protein complex involved in the inflammatory processes associated with Alzheimer's disease. By reducing neuroinflammation, the goal is to slow down the progression of Alzheimer's and improve cognitive functions. The researchers have already created a library of over 200 small molecules and have shown promising results in animal models. The study aims to refine these compounds to enhance their effectiveness and safety for potential future use in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to neuroinflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly slow the progression of Alzheimer's disease and improve quality of life for patients.
How similar studies have performed: Previous research has shown success in targeting neuroinflammation in Alzheimer's models, suggesting that this approach has potential for meaningful advancements.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Zhang, Shijun — Virginia Commonwealth University
- Study coordinator: Zhang, Shijun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.